**Core Concept**
Tyrosinemia type 1 is a rare genetic disorder caused by a deficiency in the enzyme responsible for breaking down the amino acid tyrosine. This leads to the accumulation of toxic byproducts, resulting in severe liver and kidney damage.

**Why the Correct Answer is Right**
Tyrosinemia type 1 is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase (FAH). FAH is a crucial enzyme in the catabolic pathway of tyrosine, and its deficiency leads to the accumulation of fumarylacetoacetate, which is then converted to the toxic compound succinylacetone. Succinylacetone inhibits the production of heme, leading to anemia and other complications. The deficiency of FAH is inherited in an autosomal recessive pattern, meaning that a person must inherit one defective gene from each parent to develop the condition.

**Why Each Wrong Option is Incorrect**
**Option A:** Tyrosinemia type 1 is not caused by a deficiency in the enzyme tyrosine aminotransferase (TAT), which is involved in a different step of tyrosine metabolism.
**Option B:** Phenylalanine hydroxylase deficiency is responsible for phenylketonuria (PKU), a different genetic disorder that affects the metabolism of the amino acid phenylalanine.
**Option C:** Homogentisate 1,2-dioxygenase (HGD) deficiency causes alkaptonuria, a different genetic disorder that affects the metabolism of tyrosine and phenylalanine.

**Clinical Pearl / High-Yield Fact**
Tyrosinemia type 1 is a potentially life-threatening condition that requires prompt diagnosis and treatment. Early diagnosis and initiation of treatment with NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione) can significantly improve outcomes and reduce the risk of liver and kidney damage.

**Correct Answer:** C.